Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
• Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
• Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications

Featuring perspectives from Prof John Seymour, including the following topics:

• Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
• Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
• First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications

Featuring perspectives from Dr William G Wierda, including the following topics:

• Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)
• Sequencing Road Map (12:39)
• Key Datasets — Pirtobrutinib (21:08)
• Investigator Survey (34:09)
• Chimeric Antigen Receptor T-Cell Therapy (45:08)
• Other Novel Therapy Approaches (49:58)
• EHA 2026 (54:45)

CME information and select publications

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:

• Introduction: Lymphoma Survivorship (0:00)
• Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)
• Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)

CME information and select publications

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:

• Introduction (00:00)
• Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)
• Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)
• Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)
• ASCO and EHA 2026 (46:37)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)
• Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)
• CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)
• Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24)
• Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47)

CME information and select publications

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:

• Introduction (0:00)
• The Biopathophysiology of Myelofibrosis (MF) (2:19)
• Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)
• Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)
• Upcoming at European Hematology Association (EHA) 2026 (49:22)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
• Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
• Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
• Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
• Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications